Hikma Pharmaceuticals PLC, commonly known as Hikma, is a leading global pharmaceutical company headquartered in the United Kingdom. Founded in 1978, Hikma has established a strong presence in key operational regions, including the Middle East, North Africa, and the United States. The company operates primarily in the generic and branded pharmaceuticals sectors, focusing on injectable medications, oral solids, and complex generics. Hikma is renowned for its commitment to quality and innovation, offering a diverse portfolio of products that cater to various therapeutic areas, including oncology, pain management, and infectious diseases. With a robust market position, Hikma has achieved significant milestones, including numerous FDA approvals and a growing pipeline of new therapies. The company's dedication to improving patient outcomes and expanding access to essential medicines underscores its reputation as a trusted leader in the pharmaceutical industry.
How does Hikma Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Hikma Pharmaceuticals's score of 72 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, Hikma Pharmaceuticals reported total greenhouse gas emissions of approximately 37625000 kg CO2e for Scope 1, 85682000 kg CO2e for Scope 2, and 810374000 kg CO2e for Scope 3. This reflects a comprehensive approach to emissions reporting, covering all three scopes. The company's total Scope 1 and 2 emissions combined amounted to about 123307000 kg CO2e. Hikma has set an ambitious target to reduce its Scope 1 and 2 greenhouse gas emissions by 25% by 2030, using a 2020 baseline. This commitment was established in 2021 and aims to enhance the company's sustainability efforts. Notably, since 2017, Hikma has achieved a 4% reduction in its reported GHG emissions from direct fuel usage and electricity consumption. Looking ahead, Hikma aims to achieve net zero emissions by 2050, demonstrating a long-term commitment to climate action. The company’s proactive stance on emissions reduction aligns with industry standards and reflects its dedication to environmental sustainability.
Access structured emissions data, company-specific emission factors, and source documents
2013 | 2014 | 2015 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 16,817,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 2 | 49,779,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - | - | - | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hikma Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.